Unknown

Dataset Information

0

IDALLO study: A retrospective multicenter study of the SFGM-TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1-mutated AML after allogeneic hematopoietic cell transplantation.

ABSTRACT:

SUBMITTER: Caillet A 

PROVIDER: S-EPMC10925725 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

IDALLO study: A retrospective multicenter study of the SFGM-TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1-mutated AML after allogeneic hematopoietic cell transplantation.

Caillet Adrien A   Simonet-Boissard Marion M   Forcade Edouard E   Robin Marie M   Rubio Marie-Thérèse MT   Couturier Marie-Anne MA   Srour Micha M   Maillard Natacha N   Devillier Raynier R   Huynh Anne A   Bourhis Jean-Henri JH   Simand Célestine C   Chantepie Sylvain S   Boisson Cyril C   Kroemer Marie M   Deconinck Eric E   Berceanu Ana A  

HemaSphere 20240310 3

Similar Datasets

Unknown Hepatitis E and Allogeneic Hematopoietic Stem Cell Transplantation: A French Nationwide SFGM-TC Retrospective Study.
| S-EPMC6669459 | biostudies-literature
Unknown Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
| S-EPMC7218420 | biostudies-literature
Unknown Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups.
| S-EPMC7992510 | biostudies-literature
Unknown Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.
| S-EPMC12550153 | biostudies-literature
Unknown <i>IDH1</i>-mutated relapsed or refractory AML: current challenges and future prospects.
| S-EPMC6663038 | biostudies-literature
Unknown Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
| S-EPMC10362540 | biostudies-literature
Unknown A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
| S-EPMC10320628 | biostudies-literature
Unknown Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.
| S-EPMC7933161 | biostudies-literature
Unknown Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation.
| S-EPMC6650729 | biostudies-literature
Unknown Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
| S-EPMC8464620 | biostudies-literature